0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > IL-1 RAcP

IL-1 RAcP

Brief Information

Name:Interleukin-1 receptor accessory protein
Target Synonym:Interleukin-1 receptor 3,IL-1RAcP,IL-1 receptor accessory protein,IL-1R-3,C3orf13,Interleukin 1 Receptor Accessory Protein,IL1R3,Interleukin-1 Receptor Accessory Protein Beta,IL-1R3
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

ILP-H82F5-ELISA
 IL-1 RAcP ELISA

Immobilized Human Anti-IL1RAP Human IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Human IL-1 RAcP Protein, Fc,Avitag (Cat. No. ILP-H82F5) with a linear range of 0.5-16 ng/mL (QC tested).

ILP-H82F5-MALS-HPLC
IL-1 RAcP MALS images

The purity of Biotinylated Human IL-1 RAcP Protein, Fc,Avitag (Cat. No. ILP-H82F5) is more than 85% and the molecular weight of this protein is around 155-175 kDa verified by SEC-MALS.

Synonym Name

IL1RAP,IL-1RAcP,C3orf13,IL1R3

Background

Interleukin-1 receptor accessory protein (IL1RAP or IL-1RAcP) is also known as Interleukin-1 receptor 3 (IL-1R-3 or IL-1R3), C3orf13, which belongs to the interleukin-1 receptor family. IL1RAP contains three Ig-like C2-type (immunoglobulin-like) domains and one TIR domain. IL1RAP is detected in liver, skin, placenta, thymus and lung. IL-1R3 / IL1RAP is coreceptor with IL1R1, associates with IL1R1 bound to IL1B to form the high affinity interleukin-1 receptor complex which mediates interleukin-1-dependent activation of NF-kappa-B and other pathways.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Nidanilimab CAN-04 Phase 2 Clinical Lund University Foundation Solid tumours; Biliary Tract Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma Details
CCTx-001 CCTx-001 Phase 2 Clinical Advesya SAS Leukemia, Myeloid, Acute Details
SAR-445399 SAR-445399 Phase 1 Clinical Sanofi Inflammation Details
GSK3903371 GSK3903371 Clinical Glaxosmithkline Plc Neoplasms Details
Nidanilimab CAN-04 Phase 2 Clinical Lund University Foundation Solid tumours; Biliary Tract Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma Details
CCTx-001 CCTx-001 Phase 2 Clinical Advesya SAS Leukemia, Myeloid, Acute Details
SAR-445399 SAR-445399 Phase 1 Clinical Sanofi Inflammation Details
GSK3903371 GSK3903371 Clinical Glaxosmithkline Plc Neoplasms Details

This web search service is supported by Google Inc.

totop

Laisser un message